ARDX Depositi SEC - Ardelyx, Inc.- Relazione annuale, dichiarazione di delega, prospetto informativo

Statistiche di base

LEI	549300F542QR4SXHCY32
CIK	1437402

SEC Filings

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Ardelyx, Inc.

SEC Filings (Chronological Order)

Questa pagina fornisce un elenco completo e cronologico dei depositi SEC, esclusi i documenti di proprietà che forniamo altrove.

August 4, 2025	EX-99.1	Ardelyx Reports Second Quarter 2025 Financial Results and Provides Business Update Company reports strong commercial performance in the second quarter, recording $97.7 million in total revenue, reflecting 33% growth year-over-year IBSRELA generated n Exhibit 99.1 Ardelyx Reports Second Quarter 2025 Financial Results and Provides Business Update Company reports strong commercial performance in the second quarter, recording $97.7 million in total revenue, reflecting 33% growth year-over-year IBSRELA generated net sales revenue of $65.0 million; XPHOZAH generated net sales revenue of $25.0 million Company ends Q2 with $238.5 million in cash, cash
August 4, 2025	EX-3.1	Second Amended and Restated Bylaws. Exhibit 3.1 SECOND AMENDED AND RESTATED BYLAWS OF ARDELYX, INC. (a Delaware corporation) TABLE OF CONTENTS Page ARTICLE I - CORPORATE OFFICES 1 1.1 REGISTERED OFFICE 1 1.2 OTHER OFFICES 1 ARTICLE II - MEETINGS OF STOCKHOLDERS 1 2.1 PLACE OF MEETINGS 1 2.2 ANNUAL MEETING 1 2.3 SPECIAL MEETING 1 2.4 ADVANCE NOTICE PROCEDURES FOR BUSINESS BROUGHT BEFORE A MEETING 2 2.5 ADVANCE NOTICE PROCEDURES FOR N
August 4, 2025	EX-10.3	Offer Letter, dated April 10, 2025 by and between Ardelyx, Inc. and James P. Brady. Exhibit 10.3 April 10, 2025 Revised James P. Brady 28 Fairbank Street Harvard, MA 01451 Dear Jamie, On behalf of Ardelyx (the “Company”), I am pleased to offer you employment in the exempt position of Chief Human Resources Officer, reporting to Mike Raab, President and Chief Executive Officer. In this role, you will be a member of the Executive Leadership Team. If you accept this offer, you and th
August 4, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 00
August 4, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 1, 2025 ARDELYX, INC. (Exa UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 1, 2025 ARDELYX, INC. (Exact name of registrant as specified in its charter) Delaware 001-36485 26-1303944 (State or other jurisdiction of incorporation) (Commission File Numbe
August 4, 2025	EX-10.2	to Lease Agreement by and between Ardelyx, Inc, and Prospect Fifth Avenue, LLC. Exhibit 10.2 FOURTH AMENDMENT TO COMMERCIAL LEASE The Parties hereto, Prospect Fifth Ave LLC, (“Landlord”) and Ardelyx, Inc. ( “Tenant”) are Parties under a certain Commercial Lease dated December 30, 2020, a Commencement Date Agreement dated March 18, 2021, a First Amendment of Lease dated April 9, 2021, a Second Amendment to Commercial Lease dated August 18, 2023, and a Third Amendment to Commer
July 3, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 30, 2025 ARDELYX, INC. (Exac UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 30, 2025 ARDELYX, INC. (Exact name of registrant as specified in its charter) Delaware 001-36485 26-1303944 (State or other jurisdiction of incorporation) (Commission File Number
July 3, 2025	EX-10.1	Fifth Amendment to Loan and Security Agreement, dated June 30, 2025, by and among the Company, SLR Investment Corp., as collateral agent, and the lenders party thereto Exhibit 10.1 FIFTH AMENDMENT TO LOAN AND SECURITY AGREEMENT June 30, 2025 THIS FIFTH AMENDMENT TO LOAN AND SECURITY AGREEMENT (this “Amendment”) is entered into as of the date first written above, by and among SLR INVESTMENT CORP., a Maryland corporation with an office located at 500 Park Avenue, 3rd Floor, New York, NY 10022 (“SLR”), as collateral agent (in such capacity, together with its succes
June 18, 2025	EX-10.1	First Amendment to the Ardelyx, Inc. Amended and Restated 2014 Equity Incentive Award Plan. Exhibit 10.1 FIRST AMENDMENT TO THE ARDELYX, INC. AMENDED AND RESTATED 2014 EQUITY INCENTIVE AWARD PLAN This First Amendment (this “Amendment”) to the Amended and Restated 2014 Equity Incentive Award Plan (the “Plan”), is made and adopted by the Board of Directors (the “Board”) of Ardelyx, Inc. (the “Company”), on April 29, 2025 (the “Adoption Date”), effective as of the date that it is approved b
June 18, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 18, 2025 ARDELYX, INC. (Exac UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 18, 2025 ARDELYX, INC. (Exact name of registrant as specified in its charter) Delaware 001-36485 26-1303944 (State or other jurisdiction of incorporation) (Commission File Number
May 1, 2025	EX-10.2	Form of Amended and Restated Change in Control and Severance Agreement for Executive Officers Other Than CEO. Exhibit 10.2 ARDELYX, INC. [THIRD] [AMENDED AND RESTATED] CHANGE IN CONTROL SEVERANCE AGREEMENT This [Third] [Amended and Restated] Change in Control Severance Agreement (the “Agreement”) is made and entered into [Date] (the “Effective Date”) by and between [Executive Name] (the “Executive”) and Ardelyx, Inc. (the “Company”). [This Agreement amends and restates in its entirety that certain [Second
May 1, 2025	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 1, 2025 ARDELYX, INC. (Exact name of registrant as specified in its charter) Delaware 001-36485 26-1303944 (State or other jurisdiction of incorporation) (Commission File Number)
May 1, 2025	EX-99.1	Ardelyx Reports First Quarter 2025 Financial Results and Provides Business Update Company reports $74.1 million in Q1 total revenue, reflecting 61% growth year-over-year IBSRELA net product sales revenue of $44.4 million; XPHOZAH net product sales re Exhibit 99.1 Ardelyx Reports First Quarter 2025 Financial Results and Provides Business Update Company reports $74.1 million in Q1 total revenue, reflecting 61% growth year-over-year IBSRELA net product sales revenue of $44.4 million; XPHOZAH net product sales revenue of $23.4 million Company ends Q1 with $214.0 million in cash, cash equivalents and investments Conference call scheduled for 4:30 P
May 1, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0
May 1, 2025	EX-10.3	Fourth Amended and Restated Non-Employee Director Compensation Program. Exhibit 10.3 ARDELYX, INC. FOURTH AMENDED AND RESTATED NON-EMPLOYEE DIRECTOR COMPENSATION PROGRAM Non-employee members of the board of directors (the “Board”) of Ardelyx, Inc. (the “Company”) shall be eligible to receive cash and equity compensation as set forth in this Non-Employee Director Compensation Program (this “Program”), which was adopted pursuant to the Board’s resolutions on May 23, 201
May 1, 2025	EX-10.1	Second Amended and Restated Executive Employment Agreement, dated April 29, 2025, by and between Ardelyx, Inc. and Michael Raab. Exhibit 10.1 SECOND AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT This Second Amended and Restated Executive Employment Agreement (the “Agreement”) is entered into as of April 29, 2025 (the “Effective Date”), by and between Michael Raab (“Executive”) and Ardelyx, Inc. (the “Company”). WHEREAS, the Company and Executive entered into that certain Amended and Restated Executive Employment Agree
April 30, 2025	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (
April 29, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 28, 2025 ARDELYX, INC. (Exa UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 28, 2025 ARDELYX, INC. (Exact name of registrant as specified in its charter) Delaware 001-36485 26-1303944 (State or other jurisdiction of incorporation) (Commission File Numbe
February 20, 2025	EX-99.1	Ardelyx Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update Company achieved significant commercial progress in 2024, finishing with total revenue of $333.6 million, including $319.2 million in U.S. Net Product Sa Exhibit 99.1 Ardelyx Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update Company achieved significant commercial progress in 2024, finishing with total revenue of $333.6 million, including $319.2 million in U.S. Net Product Sales Company reaffirms combined peak sales of IBSRELA and XPHOZAH of $1.75 Billion Company ended FY 2024 with $250.1 million in cash, cash
February 20, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 20, 2025 ARDELYX, INC. ( UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 20, 2025 ARDELYX, INC. (Exact name of registrant as specified in its charter) Delaware 001-36485 26-1303944 (State or other jurisdiction of incorporation) (Commission File Nu
February 20, 2025	EX-19.1	nsider Trading Exhibit 19.1 ARDELYX, INC. INSIDER TRADING COMPLIANCE POLICY AND PROCEDURES (As amended on February 18, 2025) Section I Summary page 1 Section II Persons covered and administration of policy page 1 Section III Policy statement page 2 Section IV Blackout periods page 3 Section V Preclearance of trades page 3 Section VI Exempt transactions page 4 Section VII Material non-public information page 5 Se
February 20, 2025	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER 001-364
January 13, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 13, 2025 ARDELYX, INC. (E UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 13, 2025 ARDELYX, INC. (Exact name of registrant as specified in its charter) Delaware 001-36485 26-1303944 (State or other jurisdiction of incorporation) (Commission File Num
November 18, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 15, 2024 ARDELYX, INC. ( UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 15, 2024 ARDELYX, INC. (Exact name of registrant as specified in its charter) Delaware 001-36485 26-1303944 (State or other jurisdiction of incorporation) (Commission File Nu
November 5, 2024	EX-FILING FEES	Filing Fee Table. Exhibit 107.1 Calculation of Filing Fee Tables Form S-8 (Form Type) Ardelyx, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit(2) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common stock, $0.0001 par val
November 5, 2024	S-8	As filed with the Securities and Exchange Commission on November 5, 2024 As filed with the Securities and Exchange Commission on November 5, 2024 Registration No.
October 31, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 31, 2024 ARDELYX, INC. (E UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 31, 2024 ARDELYX, INC. (Exact name of registrant as specified in its charter) Delaware 001-36485 26-1303944 (State or other jurisdiction of incorporation) (Commission File Num
October 31, 2024	EX-10.6	Offer Letter, dated July 25, 2024 by and between Alderyx, Inc. and Eric Foster. Exhibit 10.6 July 25, 2024 Eric Foster Dear Eric, On behalf of Ardelyx (the “Company”), I am pleased to offer you employment in the exempt position of Chief Commercial Officer, reporting to Mike Raab, President and Chief Executive Officer. In this role, you will be a member of the Executive Leadership Team. If you accept this offer, you and the Company will enter into a Change in Control Severance
October 31, 2024	EX-10.2	Commercial Supply Agreement, dated October 25, 2024, by and among Ardelyx, Inc., Hovione Farmaciência, S.A. and Hovione, LLC Exhibit 10.2 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE COMPANY TREATS AS PRIVATE OR CONFIDENTIAL Commercial Supply Agreement THIS COMMERCIAL SUPPLY AGREEMENT (this “Agreement”) is made as of October 21, 2024 (the “Effective Date”) by and between Hovione Farmaciência, S.A., having a principal place of business
October 31, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36485 ARDELYX, INC.
October 31, 2024	EX-10.5	Fourth Amendment to the Loan and Security Agreement dated October 29, 2024, by and between Ardelyx, Inc. and SLR Investment Corp. Exhibit 10.5 FOURTH AMENDMENT TO LOAN AND SECURITY AGREEMENT THIS FOURTH AMENDMENT TO LOAN AND SECURITY AGREEMENT (this “Amendment”) is entered into as of October 29, 2024, by and among SLR INVESTMENT CORP., a Maryland corporation with an office located at 500 Park Avenue, 3rd Floor, New York, NY 10022 (“SLR”), as collateral agent (in such capacity, together with its successors and assigns, “Colla
October 31, 2024	EX-99.1	Ardelyx Reports Third Quarter 2024 Financial Results and Provides Business Update IBSRELA generates $40.6 million in net product sales revenue; Company expects full year 2024 IBSRELA net sales revenue to be between $145 and $150 million XPHOZAH gener Exhibit 99.1 Ardelyx Reports Third Quarter 2024 Financial Results and Provides Business Update IBSRELA generates $40.6 million in net product sales revenue; Company expects full year 2024 IBSRELA net sales revenue to be between $145 and $150 million XPHOZAH generates $51.5 million in net product sales revenue Company ends Q3 with approximately $190 million in cash, cash equivalents and investments
October 9, 2024	EX-10.1	Lease Agreement, dated October 3, 2024, by and between Ardelyx, Inc. and BMR-Pacific Research Center LP. Exhibit 10.1 LEASE by and between BMR-PACIFIC RESEARCH CENTER LP, a Delaware limited partnership and ARDELYX, INC., a Delaware corporation Table of Contents 1. Lease of Premises 1 2. Basic Lease Provisions 1 3. Term 4 1. Possession and Commencement Date. 4 4. Condition of Premises 7 5. Rentable Area 7 6. Rent 7 7. Rent Adjustments; Free Rent Period 8 8. Operating Expenses 9 9. Taxes on Tenant’s Pr
October 9, 2024	EX-10.2	Sixth Amendment to Lease, dated May 25, 2021, by and between Ardelyx, Inc. and 34175 Ardenwood Venture, LLC. Exhibit 10.2 SIXTH AMENDMENT TO LEASE THIS SIXTH AMENDMENT TO LEASE (this “Amendment”) is entered into as of this 3rd day of October, 2024, by and between BMR-34175 ARDENWOOD BOULEVARD LLC, a Delaware limited liability company (“Landlord,” as successor-in-interest to Ardenwood Venture, LLC), and ARDELYX, INC., a Delaware corporation (“Tenant”). RECITALS A.WHEREAS, Landlord and Tenant are parties t
October 9, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 3, 2024 ARDELYX, INC. (Ex UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 3, 2024 ARDELYX, INC. (Exact name of registrant as specified in its charter) Delaware 001-36485 26-1303944 (State or other jurisdiction of incorporation) (Commission File Numb
August 12, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2024 ARDELYX, INC. (Exa UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2024 ARDELYX, INC. (Exact name of registrant as specified in its charter) Delaware 001-36485 26-1303944 (State or other jurisdiction of incorporation) (Commission File Numbe
August 12, 2024	EX-10.1	Commercial Supply Agreement, dated August 7, 2024 and effective as of July 23, 2024, by and between Ardelyx, Inc. and Catalent. EXHIBIT 10.1 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE COMPANY TREATS AS PRIVATE OR CONFIDENTIAL. COMMERCIAL SUPPLY AGREEMENT Tenapanor hydrochloride tablets This Commercial Supply Agreement (together with its Schedule(s), the “Agreement”) is made as of this 23rd day of July 2024 (the “Effective Date”), by an
August 1, 2024	EX-10.2	Ardelyx, Inc. Amended and Restated 2014 Employee Stock Purchase Plan. Exhibit 10.2 ARDELYX, INC. AMENDED AND RESTATED 2014 EMPLOYEE STOCK PURCHASE PLAN ARTICLE I. PURPOSE, SCOPE AND ADMINISTRATION OF THE PLAN I.1Purpose and Scope. The purpose of the Amended and Restated Ardelyx, Inc. 2014 Employee Stock Purchase Plan, as it may be amended from time to time (the “Plan”) is to assist employees of Ardelyx, Inc., a Delaware corporation, (the “Company”) and its Designate
August 1, 2024	EX-99.1	Ardelyx Reports Second Quarter 2024 Financial Results and Provides Business Update IBSRELA generates $35.4 million in net product sales revenue XPHOZAH generates $37.1 million in net product sales revenue Company ends Q2 with approximately $186 milli Exhibit 99.1 Ardelyx Reports Second Quarter 2024 Financial Results and Provides Business Update IBSRELA generates $35.4 million in net product sales revenue XPHOZAH generates $37.1 million in net product sales revenue Company ends Q2 with approximately $186 million in cash and investments Conference call scheduled for 4:30 PM Eastern Time WALTHAM, Mass., August 1, 2024 - Ardelyx, Inc. (Nasdaq: ARD
August 1, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36485 ARDELYX, INC.
August 1, 2024	EX-10.1	Ardelyx, Inc. Amended and Restated 2014 Equity Incentive Award Plan. Exhibit 10.1 ARDELYX, INC. AMENDED AND RESTATED 2014 EQUITY INCENTIVE AWARD PLAN ARTICLE 1. PURPOSE The purpose of the Ardelyx, Inc. Amended and Restated 2014 Equity Incentive Award Plan (as it may be amended from time to time, the “Plan”) is to promote the success and enhance the value of Ardelyx, Inc. (the “Company”) by linking the individual interests of the members of the Board, Employees, and
August 1, 2024	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 1, 2024 ARDELYX, INC. (Exact name of registrant as specified in its charter) Delaware 001-36485 26-1303944 (State or other jurisdiction of incorporation) (Commission File Numbe
July 2, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 2, 2024 ARDELYX, INC. (Exact UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 2, 2024 ARDELYX, INC. (Exact name of registrant as specified in its charter) Delaware 001-36485 26-1303944 (State or other jurisdiction of incorporation) (Commission File Number)
June 17, 2024	EX-10.1	Ardelyx, Inc. Amended and Restated 2014 Employee Stock Purchase Plan Exhibit 10.2 ARDELYX, INC. AMENDED AND RESTATED 2014 EMPLOYEE STOCK PURCHASE PLAN ARTICLE I. PURPOSE, SCOPE AND ADMINISTRATION OF THE PLAN I.1Purpose and Scope. The purpose of the Amended and Restated Ardelyx, Inc. 2014 Employee Stock Purchase Plan, as it may be amended from time to time (the “Plan”) is to assist employees of Ardelyx, Inc., a Delaware corporation, (the “Company”) and its Designate
June 17, 2024	EX-10.2	Ardelyx, Inc. Amended and Restated 2014 Equity Incentive Award Plan. Exhibit 10.1 ARDELYX, INC. AMENDED AND RESTATED 2014 EQUITY INCENTIVE AWARD PLAN ARTICLE 1. PURPOSE The purpose of the Ardelyx, Inc. Amended and Restated 2014 Equity Incentive Award Plan (as it may be amended from time to time, the “Plan”) is to promote the success and enhance the value of Ardelyx, Inc. (the “Company”) by linking the individual interests of the members of the Board, Employees, and
June 17, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 14, 2024 ARDELYX, INC. (Exac UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 14, 2024 ARDELYX, INC. (Exact name of registrant as specified in its charter) Delaware 001-36485 26-1303944 (State or other jurisdiction of incorporation) (Commission File Number
June 4, 2024	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Defi
May 23, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 22, 2024 ARDELYX, INC. (Exact UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 22, 2024 ARDELYX, INC. (Exact name of registrant as specified in its charter) Delaware 001-36485 26-1303944 (State or other jurisdiction of incorporation) (Commission File Number)
May 2, 2024	EX-10.3(B)	Amendment Number 2 to Lease Agreement by and between Ardelyx, Inc, and Prospect Fifth Avenue, LLC. Exhibit 10.3(b) Second Amendment to Commercial Lease The Parties hereto, Prospect Fifth Ave LLC, (“Landlord”) and Ardelyx, Inc. ( “Tenant”) are Parties under a certain Commercial Lease dated December 30, 2020 and a First Amendment of Lease dated April 9, 2021 (jointly the “Lease Agreement”) for approximately 12,864 rentable square feet on the second (2nd) and third (3rd) floors at 400 Fifth Avenue
May 2, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36485 ARDELYX, INC.
May 2, 2024	EX-99.1	Ardelyx Reports First Quarter 2024 Financial Results and Provides Business Update Company reports $45.6 million in Q1 product-related revenue, including $28.4 million in net product sales revenue for IBSRELA and $15.2 million in net product sales rev Exhibit 99.1 Ardelyx Reports First Quarter 2024 Financial Results and Provides Business Update Company reports $45.6 million in Q1 product-related revenue, including $28.4 million in net product sales revenue for IBSRELA and $15.2 million in net product sales revenue for XPHOZAH Company ends Q1 with approximately $203 million in cash and investments Conference call scheduled for 4:30 PM Eastern Ti
May 2, 2024	EX-10.29	Offer Letter, dated February 13, 2024 by and between Ardelyx, Inc. and Michael Kelliher. Exhibit 10.29 February 13, 2024 Michael Kelliher Dear Mike, On behalf of Ardelyx (the “Company”), I am pleased to offer you employment in the exempt position of Executive Vice President, Corporate Development and Strategy, reporting to Mike Raab, President and Chief Executive Officer. In this role, you will be a member of the Executive Leadership Team. You will be primarily located in Chicago, Ill
May 2, 2024	EX-10.3(C)	Amendment Number 3 to Lease Agreement by and between Ardelyx, Inc, and Prospect Fifth Avenue, LLC. Exhibit 10.3(c) Third Amendment to Commercial Lease The Parties hereto, Prospect Fifth Ave LLC, (“Landlord”) and Ardelyx, Inc. ( “Tenant”) are Parties under a certain Commercial Lease dated December 30, 2020, a Commencement Date Agreement dated March 18, 2021, a First Amendment of Lease dated April 9, 2021, and a Second Amendment to Commercial Lease dated August 18, 2023 (collectively the “Lease A
May 2, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 2, 2024 ARDELYX, INC. (Exact UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 2, 2024 ARDELYX, INC. (Exact name of registrant as specified in its charter) Delaware 001-36485 26-1303944 (State or other jurisdiction of incorporation) (Commission File Number)
April 29, 2024	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by
March 5, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 1, 2024 ARDELYX, INC. (Exac UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 1, 2024 ARDELYX, INC. (Exact name of registrant as specified in its charter) Delaware 001-36485 26-1303944 (State or other jurisdiction of incorporation) (Commission File Number
February 28, 2024	S-8	As filed with the Securities and Exchange Commission on February 27, 2024 As filed with the Securities and Exchange Commission on February 27, 2024 Registration No.
February 28, 2024	EX-FILING FEES	Filing Fee Table. Exhibit 107.1 Calculation of Filing Fee Tables Form S-8 (Form Type) Ardelyx, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit(2) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common stock, $0.0001 par val
February 22, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 22, 2024 ARDELYX, INC. ( UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 22, 2024 ARDELYX, INC. (Exact name of registrant as specified in its charter) Delaware 001-36485 26-1303944 (State or other jurisdiction of incorporation) (Commission File Nu
February 22, 2024	EX-10.7(A)	Ardelyx, Inc. 2016 Employment Commencement Incentive Plan Exhibit 10.7(a) ARDELYX, INC. 2016 EMPLOYMENT COMMENCEMENT INCENTIVE PLAN ARTICLE 1. PURPOSE The purpose of the Ardelyx, Inc. 2016 Employment Commencement Incentive Plan (as it may be amended from time to time, the “Plan”) is to promote the success and enhance the value of Ardelyx, Inc. (the “Company”) by linking the individual interests of the Eligible Individuals to those of the Company’s stockh
February 22, 2024	EX-10.20(B)	Non-Employee Director Compensation P Exhibit 10.20(b) ARDELYX, INC. THIRD AMENDED AND RESTATED NON-EMPLOYEE DIRECTOR COMPENSATION PROGRAM Non-employee members of the board of directors (the “Board”) of Ardelyx, Inc. (the “Company”) shall be eligible to receive cash and equity compensation as set forth in this Non-Employee Director Compensation Program (this “Program”), which was adopted pursuant to the Board’s resolutions on May 23,
February 22, 2024	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER 001-364
February 22, 2024	EX-97.1	Policy for Recovery of Erroneously Awarded Compensation Exhibit 97.1 ARDELYX, INC. POLICY FOR RECOVERY OF ERRONEOUSLY AWARDED COMPENSATION Ardelyx, Inc. (the “Company”) has adopted this Policy for Recovery of Erroneously Awarded Compensation (the “Policy”), effective as of October 2, 2023 or such later date when Listing Rule 5608 of the Nasdaq Stock Market (“Nasdaq”) becomes effective (the “Effective Date”). Capitalized terms used in this Policy but no
February 22, 2024	EX-99.1	Ardelyx Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update Strong commercial performance of IBSRELA continues, ending FY 2023 with $80.1 million in net product sales revenue; 2024 net product sales revenue curren Exhibit 99.1 Ardelyx Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update Strong commercial performance of IBSRELA continues, ending FY 2023 with $80.1 million in net product sales revenue; 2024 net product sales revenue currently expected to be between $140.0 to $150.0 million XPHOZAH launch off to a strong start, ending FY 2023 with $2.5 million in net product
February 13, 2024	SC 13G	ARDX / Ardelyx, Inc. / VANGUARD GROUP INC - SCHEDULE 13G Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 Name of issuer: Ardelyx Inc Title of Class of Securities: Common Stock CUSIP Number: 039697107 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule 13d-1(b) ☐ Rule 13d-1(
January 31, 2024	SC 13G/A	ARDX / Ardelyx, Inc. / MILLENNIUM MANAGEMENT LLC Passive Investment SC 13G/A 1 ARDXSC13GA12024.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (AMENDMENT NO. 1) ARDELYX, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.0001 PER SHARE (Title of Class of Securities) 039697107 (CUSIP Number) DECEMBER 31, 2023 (Date of event which requires filing of this statement) Check the appropriate
January 8, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 8, 2024 ARDELYX, INC. (Ex UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 8, 2024 ARDELYX, INC. (Exact name of registrant as specified in its charter) Delaware 001-36485 26-1303944 (State or other jurisdiction of incorporation) (Commission File Numb
November 13, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 13, 2023 ARDELYX, INC. ( UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 13, 2023 ARDELYX, INC. (Exact name of registrant as specified in its charter) Delaware 001-36485 26-1303944 (State or other jurisdiction of incorporation) (Commission File Nu
October 31, 2023	EX-99.1	Ardelyx Reports Third Quarter 2023 Financial Results and Updates 2023 U.S. IBSRELA® Net Sales Revenue Guidance Continued successful launch of IBSRELA, with Q3 net sales revenue of $22.3 million; Company currently expects 2023 full year IBSRELA U.S. n Exhibit 99.1 Ardelyx Reports Third Quarter 2023 Financial Results and Updates 2023 U.S. IBSRELA® Net Sales Revenue Guidance Continued successful launch of IBSRELA, with Q3 net sales revenue of $22.3 million; Company currently expects 2023 full year IBSRELA U.S. net sales revenue to be $76 to $78 million XPHOZAH® launch underway following October 17, 2023 FDA approval Company ends Q3 with $165.1 mi
October 31, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36485 ARDELYX, INC.
October 31, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 31, 2023 ARDELYX, INC. (E UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 31, 2023 ARDELYX, INC. (Exact name of registrant as specified in its charter) Delaware 001-36485 26-1303944 (State or other jurisdiction of incorporation) (Commission File Num
October 18, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 17, 2023 ARDELYX, INC. (E UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 17, 2023 ARDELYX, INC. (Exact name of registrant as specified in its charter) Delaware 001-36485 26-1303944 (State or other jurisdiction of incorporation) (Commission File Num
October 18, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 17, 2023 ARDELYX, INC. (E UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 17, 2023 ARDELYX, INC. (Exact name of registrant as specified in its charter) Delaware 001-36485 26-1303944 (State or other jurisdiction of incorporation) (Commission File Num
October 18, 2023	EX-10.1	mendment to the Loan and Security Agreement dated October 17, 2023, by and between Ardelyx Exhibit 10.1 THIRD AMENDMENT TO LOAN AND SECURITY AGREEMENT THIS THIRD AMENDMENT TO LOAN AND SECURITY AGREEMENT (this “Amendment”) is entered into as of October 17, 2023, by and among SLR INVESTMENT CORP., a Maryland corporation with an office located at 500 Park Avenue, 3rd Floor, New York, NY 10022 (“SLR”), as collateral agent (in such capacity, together with its successors and assigns, “Collate
September 25, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 25, 2023 ARDELYX, INC. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 25, 2023 ARDELYX, INC. (Exact name of registrant as specified in its charter) Delaware 001-36485 26-1303944 (State or other jurisdiction of incorporation) (Commission File N
August 2, 2023	EX-99.1	Ardelyx Reports Second Quarter 2023 Financial Results and Provides 2023 IBSRELA Net Sales Revenue Guidance Continued successful launch of IBSRELA, with Q2 net sales revenue of $18.3 million; Company currently expects 2023 full year IBSRELA net sales Exhibit 99.1 Ardelyx Reports Second Quarter 2023 Financial Results and Provides 2023 IBSRELA Net Sales Revenue Guidance Continued successful launch of IBSRELA, with Q2 net sales revenue of $18.3 million; Company currently expects 2023 full year IBSRELA net sales revenue to be $72 to $77 million XPHOZAH expected to launch in Q4, pending FDA approval Company ends Q2 with $127.6 million in cash and i
August 2, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 2, 2023 ARDELYX, INC. (Exa UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 2, 2023 ARDELYX, INC. (Exact name of registrant as specified in its charter) Delaware 001-36485 26-1303944 (State or other jurisdiction of incorporation) (Commission File Numbe
August 2, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36485 ARDELYX, INC.
July 10, 2023	SC 13G	ARDX / Ardelyx Inc / STATE STREET CORP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 INITIAL FILING ARDELYX INC (NAME OF ISSUER) COMMON STOCK (TITLE OF CLASS OF SECURITIES) 039697107 (CUSIP NUMBER) 06/30/2023 (DATE OF EVENT WHICH REQUIRES FILING OF THIS STATEMENT) CHECK THE APPROPRIATE BOX TO DESIGNATE THE RULE PURSUANT TO WHICH THIS SCHEDULE IS FILED: (X)
June 20, 2023	EX-3.1	Certificate of Amendment to Amended and Restated Certificate of Incorporation. Exhibit 3.1 CERTIFICATE OF AMENDMENT OF THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF ARDELYX, INC. June 16, 2023 Ardelyx, Inc. (the “Corporation”), a corporation organized and existing under the General Corporation Law of the State of Delaware (the “DGCL”), hereby certifies that: 1.The name of the Corporation is Ardelyx, Inc. 2.This Certificate of Amendment (this “Certificate of Amendm
June 20, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 15, 2023 ARDELYX, INC. (Exac UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 15, 2023 ARDELYX, INC. (Exact name of registrant as specified in its charter) Delaware 001-36485 26-1303944 (State or other jurisdiction of incorporation) (Commission File Number
June 5, 2023	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Definitive Proxy State
May 17, 2023	EX-99.1	Ardelyx Announces FDA Acceptance and Six-Month Review for Resubmission of its New Drug Application of XPHOZAH® (tenapanor) User Fee Goal Date: October 17, 2023 Ardelyx Announces FDA Acceptance and Six-Month Review for Resubmission of its New Drug Application of XPHOZAH® (tenapanor) User Fee Goal Date: October 17, 2023 WALTHAM, Mass.
May 17, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 17, 2023 ARDELYX, INC. (Exact UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 17, 2023 ARDELYX, INC. (Exact name of registrant as specified in its charter) Delaware 001-36485 26-1303944 (State or other jurisdiction of incorporation) (Commission File Number)
May 3, 2023	EX-99.1	Ardelyx Reports First Quarter 2023 Financial Results and Provides Business Update Continued successful launch of IBSRELA, with Q1 net product sales of $11.4 million XPHOZAH New Drug Application resubmitted on April 17, 2023 Company ends Q1 with over Exhibit 99.1 Ardelyx Reports First Quarter 2023 Financial Results and Provides Business Update Continued successful launch of IBSRELA, with Q1 net product sales of $11.4 million XPHOZAH New Drug Application resubmitted on April 17, 2023 Company ends Q1 with over $130 million in cash and investments Conference call scheduled for 4:30 PM Eastern Time WALTHAM, Mass., May 3, 2023 - Ardelyx, Inc. (Nasd
May 3, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36485 ARDELYX, INC.
May 3, 2023	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 3, 2023 ARDELYX, INC. (Exact name of registrant as specified in its charter) Delaware 001-36485 26-1303944 (State or other jurisdiction of incorporation) (Commission File Number)
April 26, 2023	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by
April 14, 2023	PRE 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by
March 7, 2023	EX-99.3	Ardelyx, Inc. 2016 Employment Commencement Incentive Plan, as amended. Exhibit 99.3 ARDELYX, INC. 2016 EMPLOYMENT COMMENCEMENT INCENTIVE PLAN As amended ARTICLE 1. PURPOSE The purpose of the Ardelyx, Inc. 2016 Employment Commencement Incentive Plan (as amended from time to time, the “Plan”) is to promote the success and enhance the value of Ardelyx, Inc. (the “Company”) by linking the individual interests of the Eligible Individuals to those of the Company’s stockhol
March 7, 2023	EX-FILING FEES	Filing Fee Table. Exhibit 107.1 Calculation of Filing Fee Tables Form S-8 (Form Type) Ardelyx, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit(2) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common stock, $0.0001 par val
March 7, 2023	S-8	As filed with the Securities and Exchange Commission on March 6, 2023 As filed with the Securities and Exchange Commission on March 6, 2023 Registration No.
March 2, 2023	EX-10.21(B)	Amendment Number 1 to License Agreement, dated as of November 27, 2017, by and among Ardelyx, Inc., and Kyowa Kirin Co., Ltd. Ex. 10.21(b) AMENDMENT NO. 1 to LICENSE AGREEMENT This FIRST AMENDMENT (the ”Amendment”), effective as of the date last signed below (the ”Amendment Date”), amends that certain License Agreement dated November 27, 2017 (together with all exhibits, amendments and attachments thereto, the "Original Agreement”) by and between Kyowa Kirin Co., Ltd. (f/k/a Kyowa Hakko Kirin Co., Ltd.), a Japanese corpo
March 2, 2023	EX-10.2(E)	Fourth Amendment to Lease, dated May 25, 2021, by and between Ardelyx, Inc. and 34175 Ardenwood Venture, LLC Ex. 10.2(e) FOURTH AMENDMENT TO LEASE THIS FOURTH AMENDMENT TO LEASE (this "Fourth Amendment") is entered into as of this llth day of May, 2018 (the "Execution Date"), by and between 34175 ARDENWOOD VENTURE, LLC, a Delaware limited liability company ("Landlord"), and ARDELYX, INC., a Delaware corporation ("Tenant," formerly known as Nteryx, Inc.). RECITALS A.WHEREAS, Landlord and Tenant entered in
March 2, 2023	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2022 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER 001-364
March 2, 2023	EX-10.27(B)	First Amendment to the Manufacturing Services Agreement dated February 27, 2023, between Ardelyx, Inc. and Patheon Pharmaceuticals Inc. Ex. 10.27(b) Certain confidential information contained in this document, marked by [***], has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential. First Amendment to Manufacturing Services Agreement Between Ardelyx, Inc. and Patheon Pharmaceuticals Inc. THIS AMENDMENT NO. 1 (“Amendment 1”) is entered into by and between Ardel
March 2, 2023	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 2, 2023 ARDELYX, INC. (Exact name of registrant as specified in its charter) Delaware 001-36485 26-1303944 (State or other jurisdiction of incorporation) (Commission File Number
March 2, 2023	EX-10.24(C)	Second Amendment to the Loan and Security Agreement dated February 9, 2023, by and between Ardelyx, Inc. and SLR Investment Corp. Ex. 10.24(c) SECOND AMENDMENT TO LOAN AND SECURITY AGREEMENT THIS SECOND AMENDMENT TO LOAN AND SECURITY AGREEMENT (this “Amendment”) is entered into as of February 9, 2023, by and among SLR INVESTMENT CORP., a Maryland corporation with an office located at 500 Park Avenue, 3rd Floor, New York, NY 10022 (“SLR”), as collateral agent (in such capacity, together with its successors and assigns, “Colla
March 2, 2023	EX-99.1	Ardelyx Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update Continued successful launch of IBSRELA, ending FY 2022 with $15.6 million in net product sales Resubmission of XPHOZAH New Drug Application expected in e Exhibit 99.1 Ardelyx Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update Continued successful launch of IBSRELA, ending FY 2022 with $15.6 million in net product sales Resubmission of XPHOZAH New Drug Application expected in early-Q2 2023 Company ends Q4 with approximately $123.9 million in cash and investments Conference call scheduled for 4:30 PM Eastern Time
February 15, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 9, 2023 ARDELYX, INC. (E UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 9, 2023 ARDELYX, INC. (Exact name of registrant as specified in its charter) Delaware 001-36485 26-1303944 (State or other jurisdiction of incorporation) (Commission File Num
February 14, 2023	SC 13G/A	ARDX / Ardelyx Inc / Deep Track Capital, LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No.
February 7, 2023	SC 13G	ARDX / Ardelyx Inc / MILLENNIUM MANAGEMENT LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 ARDELYX, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.0001 PER SHARE (Title of Class of Securities) 039697107 (CUSIP Number) FEBRUARY 3, 2023 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pursuant to which this
January 27, 2023	SC 13G/A	ARDX / Ardelyx Inc / MILLENNIUM MANAGEMENT LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (AMENDMENT NO. 1) ARDELYX, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.0001 PER SHARE (Title of Class of Securities) 039697107 (CUSIP Number) DECEMBER 31, 2022 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule purs
January 24, 2023	CORRESP	Ardelyx, Inc. 400 Fifth Avenue, Suite 210 Waltham, MA 02451 CORRESP 1 filename1.htm Ardelyx, Inc. 400 Fifth Avenue, Suite 210 Waltham, MA 02451 January 24, 2023 VIA EDGAR AND E-MAIL United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549-6010 Attention: Tyler Howes Re: Ardelyx, Inc. Registration Statement on Form S-3 Filed January 19, 2023 File No. 333-269297 To the
January 24, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 18, 2023 ARDELYX, INC. (E UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 18, 2023 ARDELYX, INC. (Exact name of registrant as specified in its charter) Delaware 001-36485 26-1303944 (State or other jurisdiction of incorporation) (Commission File Num
January 19, 2023	EX-4.2	Form of Indenture Exhibit 4.2 ARDELYX, INC. INDENTURE Dated as of , 20 [], as Trustee TABLE OF CONTENTS Page ARTICLE I. DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.1. Definitions 1 Section 1.2. Other Definitions 4 Section 1.3. Incorporation by Reference of Trust Indenture Act 4 Section 1.4. Rules of Construction 5 ARTICLE II. THE SECURITIES 5 Section 2.1. Issuable in Series 5 Section 2.2. Establishment o
January 19, 2023	S-3	As filed with the Securities and Exchange Commission on January 18, 2023 Table of Contents As filed with the Securities and Exchange Commission on January 18, 2023 Registration No.
January 19, 2023	EX-FILING FEES	Fee Table Exhibit Exhibit 107.1 Calculation of Filing Fee Tables Form S-3 (Form Type) Ardelyx, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry F
January 19, 2023	EX-1.2	Open Market Sales Agreement, dated January 18, 2023 between Ardelyx, Inc. and Jefferies LLC. Exhibit 1.2 OPEN MARKET SALE AGREEMENTSM January 18, 2023 JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: Ardelyx, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the “Agent”), shares of the Company’s common stock, pa
December 29, 2022	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 27, 2022 ARDELYX, INC. ( UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 27, 2022 ARDELYX, INC. (Exact name of registrant as specified in its charter) Delaware 001-36485 26-1303944 (State or other jurisdiction of incorporation) (Commission File Nu
December 2, 2022	SC 13G	ARDX / Ardelyx Inc / MILLENNIUM MANAGEMENT LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 ARDELYX, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.0001 PER SHARE (Title of Class of Securities) 039697107 (CUSIP Number) NOVEMBER 25, 2022 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pursuant to which this
November 3, 2022	EX-99.1	Ardelyx Reports Third Quarter 2022 Financial Results and Recent Business Highlights Conference call scheduled for 4:30 p.m. Eastern Time today Exhibit 99.1 Ardelyx Reports Third Quarter 2022 Financial Results and Recent Business Highlights Conference call scheduled for 4:30 p.m. Eastern Time today WALTHAM, Mass., November 3, 2022 - Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative first-in-class medicines that meet significant unmet medical needs, today repo
November 3, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36485 ARDELYX, INC.
November 3, 2022	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 3, 2022 ARDELYX, INC. (E UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 3, 2022 ARDELYX, INC. (Exact name of registrant as specified in its charter) Delaware 001-36485 26-1303944 (State or other jurisdiction of incorporation) (Commission File Num
September 19, 2022	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 19, 2022 ARDELYX, INC. (Exact name of registrant as specified in its charter) Delaware 001-36485 26-1303944 (State or other jurisdiction of incorporation) (Commission File N
September 12, 2022	SC 13G	ARDX / Ardelyx Inc / Deep Track Capital, LP Passive Investment SC 13G 1 deeptrack-ardx090222.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* ARDELYX, INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 039697107 (CUSIP Number) September 02, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropria
August 4, 2022	EX-10.3	Second Amended and Restated Non-Employee Director Compensation Program Exhibit 10.3 ARDELYX, INC. SECOND AMENDED AND RESTATED NON-EMPLOYEE DIRECTOR COMPENSATION PROGRAM Non-employee members of the board of directors (the ?Board?) of Ardelyx, Inc. (the ?Company?) shall be eligible to receive cash and equity compensation as set forth in this Non-Employee Director Compensation Program (this ?Program?), which was adopted pursuant to the Board?s resolutions on May 23, 201
August 4, 2022	EX-10.2	First Amendment to the Loan and Security Agreement dated August 1, 2022, by and between Ardelyx, Inc. and SLR Investment Corp. Exhibit 10.2 FIRST AMENDMENT TO LOAN AND SECURITY AGREEMENT THIS FIRST AMENDMENT TO LOAN AND SECURITY AGREEMENT (this ?Amendment?) is entered into as of August 1, 2022, by and among SLR INVESTMENT CORP., a Maryland corporation with an office located at 500 Park Avenue, 3rd Floor, New York, NY 10022 (?SLR?), as collateral agent (in such capacity, together with its successors and assigns, ?Collatera
August 4, 2022	EX-99.1	Ardelyx Reports Second Quarter 2022 Financial Results and Recent Business Highlights Conference call scheduled for 4:30 p.m. Eastern Time today Exhibit 99.1 Ardelyx Reports Second Quarter 2022 Financial Results and Recent Business Highlights Conference call scheduled for 4:30 p.m. Eastern Time today WALTHAM, Mass., Aug 4, 2022 - Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative first-in-class medicines that meet significant unmet medical needs, today reported
August 4, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36485 ARDELYX, INC.
August 4, 2022	EX-10.1	Royalty and Sales Milestone Interest Acquisition Agreement dated June 29, 2022, by and between Ardelyx, Inc. and Healthcare Royalty Partners IV, L.P. Exhibit 10.1 Certain confidential information contained in this document, marked by [***], has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential. EXECUTION COPY ROYALTY AND SALES MILESTONE INTEREST ACQUISITION AGREEMENT Dated as of June 29, 2022 between Ardelyx, Inc. and HealthCare Royalty Partners IV, L.P. TABLE OF CONTENTS
August 4, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2022 ARDELYX, INC. (Exact name of registrant as specified in its charter) Delaware 001-36485 26-1303944 (State or other jurisdiction of incorporation) (Commission File Numbe
July 15, 2022	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 13, 2022 ARDELYX, INC. (Exact name of registrant as specified in its charter) Delaware 001-36485 26-1303944 (State or other jurisdiction of incorporation) (Commission File Number
July 1, 2022	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.
June 30, 2022	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 29, 2022 ARDELYX, INC. (Exact name of registrant as specified in its charter) Delaware 001-36485 26-1303944 (State or other jurisdiction of incorporation) (Commission File Number
June 22, 2022	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 15, 2022 ARDELYX, INC. (Exact name of registrant as specified in its charter) Delaware 001-36485 26-1303944 (State or other jurisdiction of incorporation) (Commission File Number
June 8, 2022	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) DEFA14A 1 ardx-20220608xdefa14a.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only
May 27, 2022	8-K	Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 23, 2022 ARDELYX, INC. (Exact name of registrant as specified in its charter) Delaware 001-36485 26-1303944 (State or other jurisdiction of incorporation) (Commission File Number)
May 13, 2022	DEFR14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 1) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 1) Filed by the Registrant ? Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a?6(e)(2)) ? Defi
May 5, 2022	EX-10.2	Exit Fee Agreement dated February 23, 2022, by and between Ardelyx, Inc. and SLR Investment Corp. Exhibit 10.2 Exit Fee Agreement Reference is made to the Loan and Security Agreement, dated as of February 23, 2022 (as may be amended, amended and restated, supplemented or otherwise modified from time to time, the ?Loan Agreement?) by and among SLR Investment Corp., a Maryland corporation (?SLR?), as collateral agent (in such capacity, ?Agent?), the lenders party thereto from time to time includ
May 5, 2022	EX-99.1	Ardelyx Reports First Quarter 2022 Financial Results and Recent Business Highlights Conference Call Scheduled for 4:30 PM Eastern Time Today Exhibit 99.1 Ardelyx Reports First Quarter 2022 Financial Results and Recent Business Highlights Conference Call Scheduled for 4:30 PM Eastern Time Today WALTHAM, Mass., May 5, 2022 - Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative first-in-class medicines that meet significant unmet medical needs, today provided a
May 5, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36485 ARDELYX, INC.
May 5, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2022 ARDELYX, INC. (Exact name of registrant as specified in its charter) Delaware 001-36485 26-1303944 (State or other jurisdiction of incorporation) (Commission File Number)
May 5, 2022	EX-10.1	Loan and Security Agreement dated February 23, 2022, by and between Ardelyx, Inc. and SLR Investment Corp. Exhibit 10.1 LOAN AND SECURITY AGREEMENT THIS LOAN AND SECURITY AGREEMENT (as the same may be amended, restated, modified, or supplemented from time to time, this ?Agreement?) dated as of February 23, 2022 (the ?Effective Date?) among SLR Investment Corp., a Maryland corporation with an office located at 500 Park Avenue, 3rd Floor, New York, NY 10022 (?SLR?), as collateral agent (in such capacity,
April 29, 2022	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) DEF 14A 1 edge20003685x2def14a.htm DEF 14A TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for
April 25, 2022	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 25, 2022 ARDELYX, INC. (Exact name of registrant as specified in its charter) Delaware 001-36485 26-1303944 (State or other jurisdiction of incorporation) (Commission File Numbe
April 15, 2022	PRE 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) PRE 14A 1 edge20003685x1pre14a.htm PRE 14A TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for U
April 11, 2022	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 11, 2022 ARDELYX, INC. (Exact name of registrant as specified in its charter) Delaware 001-36485 26-1303944 (State or other jurisdiction of incorporation) (Commission File Numbe
April 11, 2022	EX-99.1	AMENDMENT NO.2 to LICENSE AGREEMENT Certain confidential information contained in this document, marked by [***], has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.
April 1, 2022	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 31, 2022 ARDELYX, INC. (Exact name of registrant as specified in its charter) Delaware 001-36485 26-1303944 (State or other jurisdiction of incorporation) (Commission File Numbe
March 14, 2022	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2022 ARDELYX, INC. (Exact name of registrant as specified in its charter) Delaware 001-36485 26-1303944 (State or other jurisdiction of incorporation) (Commission File Numbe
March 1, 2022	S-8	As filed with the Securities and Exchange Commission on March 1, 2022 As filed with the Securities and Exchange Commission on March 1, 2022 Registration No.
March 1, 2022	EX-FILING FEES	Filing Fee Table. Exhibit 107.1 Calculation of Filing Fee Tables Form S-8 (Form Type) Ardelyx, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit(2) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common stock, $0.0001 par val
February 28, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2022 ARDELYX, INC. (Exact name of registrant as specified in its charter) Delaware 001-36485 26-1303944 (State or other jurisdiction of incorporation) (Commission File Nu
February 28, 2022	EX-10.21	Executive Retention Exhibit 10.21 RETENTION AGREEMENT This Retention Agreement (?Agreement?) is made and entered into by and between Ardelyx, Inc. (?Company?) and (?Executive?), effective as of October 25, 2021 (?Effective Date?). Recitals A. The Company and the Board of Directors of the Company (?Board?) has determined that it is in the best interests of the Company and its stockholders to execute a second reduction
February 28, 2022	EX-10.19	Retention Agreement, dated October 25, 2021, by and between Ardelyx, Inc. and Justin Renz Exhibit 10.19 RETENTION AGREEMENT This Retention Agreement (?Agreement?) is made and entered into by and between Ardelyx, Inc. (?Company?) and Justin Renz (?Executive?), effective as of October 25, 2021 (?Effective Date?). Recitals A. The Company and the Board of Directors of the Company (?Board?) has determined that it is in the best interests of the Company and its stockholders to execute a seco
February 28, 2022	EX-10.16	Retention Agreement, dated October 25, 2021, Exhibit 10.16 RETENTION AGREEMENT This Retention Agreement (?Agreement?) is made and entered into by and between Ardelyx, Inc. (?Company?) and Susan Rodriguez (?Executive?), effective as of October 25, 2021 (?Effective Date?). Recitals A. The Company and the Board of Directors of the Company (?Board?) has determined that it is in the best interests of the Company and its stockholders to execute a
February 28, 2022	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2021 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER 001-364
February 28, 2022	EX-10.22	Form of Executive Retention Agreement Version 2 Exhibit 10.22 RETENTION AGREEMENT This Retention Agreement (?Agreement?) is made and entered into by and between Ardelyx, Inc. (?Company?) and (?Executive?), effective as of October 25, 2021 (?Effective Date?). Recitals A. The Company and the Board of Directors of the Company (?Board?) has determined that it is in the best interests of the Company and its stockholders to execute a second reduction
February 28, 2022	EX-10.8	by and between Ardelyx, Exhibit 10.8 RETENTION AGREEMENT This Retention Agreement (?Agreement?) is made and entered into by and between Ardelyx, Inc. (?Company?) and Michael Raab (?Executive?), effective as of October 25, 2021 (?Effective Date?). Recitals A. The Company and the Board of Directors of the Company (?Board?) has determined that it is in the best interests of the Company and its stockholders to execute a seco
February 28, 2022	EX-10.20	Amendment Number One to Second Amended and Restated Change in Control Severance Agreement and Retention Agreement dated December 1, 2021 between Ardelyx, Inc. and David Rosenbaum Exhibit 10.20 Amendment Number One To Second Amended and Restated Change in Control Severance Agreement and to Retention Agreement This Amendment Number One to Second Amended and Restated Change in Control Severance Agreement and to Retention Agreement (?Amendment Number One?) is made and entered into this first day of December, 2021, by and between David P. Rosenbaum (the ?Executive?) and Ardelyx
February 28, 2022	EX-99.1	Ardelyx Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Highlights Company Advancing Toward Launch of IBSRELA® in April 2022 Conference Call scheduled for 4:30 PM Eastern Time Exhibit 99.1 Ardelyx Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Highlights Company Advancing Toward Launch of IBSRELA? in April 2022 Conference Call scheduled for 4:30 PM Eastern Time WALTHAM, Mass., Feb 28, 2022 - Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative first-in-class medicines t
February 25, 2022	8-K	Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 23, 2022 ARDELYX, INC. (Exact name of registrant as specified in its charter) Delaware 001-36485 26-1303944 (State or other jurisdiction of incorporation) (Commission File Nu
February 15, 2022	SC 13G/A	ARDX / Ardelyx Inc / Rock Springs Capital Management LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No.
February 10, 2022	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 4, 2022 ARDELYX, INC. (E UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 4, 2022 ARDELYX, INC. (Exact name of registrant as specified in its charter) Delaware 001-36485 26-1303944 (State or other jurisdiction of incorporation) (Commission File Num
February 10, 2022	SC 13G/A	ARDX / Ardelyx Inc / ADAGE CAPITAL PARTNERS GP, L.L.C. - ARDELYX, INC. Passive Investment SC 13G/A 1 p22-0568sc13ga.htm ARDELYX, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 4)* Ardelyx, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 039697107 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of This Statement) Check the appropria
December 29, 2021	SC 13D/A	ARDX / Ardelyx Inc / New Enterprise Associates 12, Limited Partnership - NEW ENTERPRISE ASSOCIATES 12, LP (ARDELYX) - SCHEDULE 13DA7E Activist Investment Schedule 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 7)* Ardelyx, Inc. (Name of Issuer) Common Stock, $.0001 par value (Title of Class of Securities) 039697107 (CUSIP Number) Louis S. Citron, Esq. New Enterprise Associates 1954 Greenspring Drive, Suite 600, Timonium, MD 21093 (410) 842-4000 (Name,
November 30, 2021	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 30, 2021 ARDELYX, INC. (Exact name of registrant as specified in its charter) Delaware 001-36485 26-1303944 (State or other jurisdiction of incorporation) (Commission File Nu
November 15, 2021	SC 13G/A	ARDX / Ardelyx Inc / RA CAPITAL MANAGEMENT, L.P. - SCHEDULE 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Ardelyx, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 039697107 (CUSIP Number) November 15, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pur
November 12, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36485 ARDELYX, INC.
November 12, 2021	EX-99.1	Ardelyx Reports Third Quarter 2021 Financial Results Exhibit 99.1 Ardelyx Reports Third Quarter 2021 Financial Results FREMONT, Calif. and WALTHAM, Mass., November 12, 2021 - Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company focused on the discovery, development, and commercialization of innovative first-in-class medicines to improve treatment for people with kidney and cardiorenal diseases, today reported business events and financial resul
November 12, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 12, 2021 ARDELYX, INC. (Exact name of registrant as specified in its charter) Delaware 001-36485 26-1303944 (State or other jurisdiction of incorporation) (Commission File Nu
October 13, 2021	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Costs Associated with Exit or Disposal Activities UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 8, 2021 ARDELYX, INC. (Exact name of registrant as specified in its charter) Delaware 001-36485 26-1303944 (State or other jurisdiction of incorporation) (Commission File Numb
August 17, 2021	EX-10.1	Open Market Sales Agreement, dated August 31, 2021 between Ardelyx, Inc. and Jefferies LLC. Exhibit 10.1 OPEN MARKET SALE AGREEMENT1 August 13, 2021 JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: Ardelyx, Inc., a Delaware corporation (the ?Company?), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the ?Agent?), shares of the Company?s common stock, par
August 17, 2021	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 13, 2021 ARDELYX, INC. (Exact name of registrant as specified in its charter) Delaware 001-36485 26-1303944 (State or other jurisdiction of incorporation) (Commission File Numb
August 13, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 13, 2021 ARDELYX, INC. (Exact name of registrant as specified in its charter) Delaware 001-36485 26-1303944 (State or other jurisdiction of incorporation) (Commission File Numb
August 13, 2021	EX-99.1	Ardelyx Reports Second Quarter 2021 Financial Results Exhibit 99.1 Ardelyx Reports Second Quarter 2021 Financial Results FREMONT, Calif. & WALTHAM, Mass., August 13, 2021 - Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company focused on the discovery, development, and commercialization of innovative first-in-class medicines to improve treatment for people with kidney and cardiorenal diseases, today reported business events and financial results
August 13, 2021	424B5	Up to $150,000,000 Common Stock Filed Pursuant to Rule 424(b)(5) Registration Statement No. 333-239764 PROSPECTUS SUPPLEMENT Up to $150,000,000 Common Stock We have entered into a sales agreement with Jefferies LLC, or Jefferies, relating to shares of our common stock offered by this prospectus supplement and the accompanying prospectus. In accordance with the terms of the sales agreement, under this prospectus supplement we may
August 13, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36485 ARDELYX, INC.
August 3, 2021	8-K	Financial Statements and Exhibits, Costs Associated with Exit or Disposal Activities UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 29, 2021 ARDELYX, INC. (Exact name of registrant as specified in its charter) Delaware 001-36485 26-1303944 (State or other jurisdiction of incorporation) (Commission File Number
July 30, 2021	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 28, 2021 ARDELYX, INC. (Exact name of registrant as specified in its charter) Delaware 001-36485 26-1303944 (State or other jurisdiction of incorporation) (Commission File Number
July 30, 2021	EX-10.1	Fourth Amendment to the Loan and Security Agreement, dated as of July 29, 2021, by and among Ardelyx, Inc., Solar Capital Ltd. and the lenders party thereto. EX-10.1 2 fourthamendmenttoloanandse.htm EX-10.1 FOURTH AMENDMENT TO LOAN AND SECURITY AGREEMENT THIS FOURTH AMENDMENT TO LOAN AND SECURITY AGREEMENT (this “Amendment”), dated as of July 29, 2021 (the “Amendment Effective Date”), is made by and among Ardelyx, Inc., a Delaware corporation (“Borrower”), SLR Investment Corp., a Maryland corporation and formerly known as Solar Capital Ltd. (“Solar”),
July 19, 2021	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 13, 2021 ARDELYX, INC. (Exac UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 13, 2021 ARDELYX, INC. (Exact name of registrant as specified in its charter) Delaware 001-36485 26-1303944 (State or other jurisdiction of incorporation) (Commission File Number
June 21, 2021	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 16, 2021 ARDELYX, INC. (Exact name of registrant as specified in its charter) Delaware 001-36485 26-1303944 (State or other jurisdiction of incorporation) (Commission File Number
June 1, 2021	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits 8-K 1 ardx-20210601x8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 25, 2021 ARDELYX, INC. (Exact name of registrant as specified in its charter) Delaware 001-36485 26-1303944 (State or other jurisdiction of incorpor
June 1, 2021	EX-10.1	Fifth Amendment to Lease, dated May 25, 2021, by and between Ardelyx, Inc. and 34175 Ardenwood Venture, LLC Exhibit 10.1 FIFTH AMENDMENT TO LEASE THIS FIFTH AMENDMENT TO LEASE (this "Amendment") is entered into as of this 25th day of May 2021, by and between 34175 ARDENWOOD VENTURE, LLC, a Delaware limited liability company ("Landlord"), and ARDELYX, INC., a Delaware corporation ('Tenant"). RECITALS A. WHEREAS, Landlord and Tenant are parties to that certain Lease dated as of August 8, 2008 (the "Origin
May 6, 2021	10-Q	Quarterly Report - 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36485 ARDELYX, INC.
May 6, 2021	EX-99.1	Ardelyx Reports First Quarter 2021 Financial Results and Recent Business Highlights Exhibit 99.1 Ardelyx Reports First Quarter 2021 Financial Results and Recent Business Highlights FREMONT, Calif. & WALTHAM, Mass., May 6, 2021 - Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company focused on developing innovative first-in-class medicines to improve treatment for people with kidney and cardiorenal diseases, today reported business highlights and financial results for the firs
May 6, 2021	EX-10.1	, 2021, by and between the Company and Solar Capital Ltd. and Western Alliance Bank. Exhibit 10.1 THIRD AMENDMENT TO LOAN AND SECURITY AGREEMENT THIS THIRD AMENDMENT TO LOAN AND SECURITY AGREEMENT (this ?Amendment?), dated as of May 5, 2021 (the ?Amendment Effective Date?), is made by and among Ardelyx, Inc., a Delaware corporation (?Borrower?), SLR Investment Corp., a Maryland corporation and formerly known as Solar Capital Ltd. (?Solar?), in its capacity as collateral agent for
May 6, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2021 ARDELYX, INC. (Exact name of registrant as specified in its charter) Delaware 001-36485 26-1303944 (State or other jurisdiction of incorporation) (Commission File Number)
May 3, 2021	8-K	Financial Statements and Exhibits, Other Events ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ? FORM 8-K ? CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 29, 2021 ? ARDELYX, INC. (Exact name of registrant as specified in its charter) ? Delaware 001-36485 26-1303944 (State or other jurisdiction of incorporation) (Commissio
April 30, 2021	DEF 14A	10-K for the year ended December 31, 2020 from our Definitive Proxy Statement on Schedule TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.?) Filed by the Registrant ? ?????Filed by a party other than the Registrant ?? Check the appropriate box: ?? ? ? Preliminary Proxy Statement ?? ? ? Confidential, for Use of the Commission Only (as perm
April 30, 2021	DEFA14A	- DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a‑6(e)(2)) ☐ Defin
March 15, 2021	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 11, 2021 ARDELYX, INC. (Exact name of registrant as specified in its charter) - Delaware 001-36485 26-1303944 (State or other jurisdiction of incorporation) (Commission File Num
March 12, 2021	S-8	- S-8 As filed with the Securities and Exchange Commission on March 11, 2021 Registration No.
March 8, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ? FORM 8-K ? CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 8, 2021 ? ARDELYX, INC. (Exact name of registrant as specified in its charter) ? Delaware 001-36485 26-1303944 (State or other jurisdiction of incorporation) (Commission
March 8, 2021	10-K	Annual Report - 10-K Table of Contents ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.
March 8, 2021	EX-99.1	Ardelyx Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Highlights Company well positioned for PDUFA date of April 29, 2021 and the potential launch of tenapanor ? Exhibit 99.1 Ardelyx Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Highlights Company well positioned for PDUFA date of April 29, 2021 and the potential launch of tenapanor FREMONT, Calif./ WALTHAM, Mass., March 8, 2021 - Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company focused on developing innovative first-in-class medicines to improve treatment for people wit
March 8, 2021	EX-4.4	Description of the Registrant’s Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934 ? ? ? Exhibit 4.4 DESCRIPTION OF THE REGISTRANT?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 ? ? Ardelyx, Inc. (?we,? ?us,? or ?our?) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended: our common stock, $0.0001 par value per share (?common stock?). ? Description of Capital Stock ? The following summar
March 8, 2021	EX-10.31	Lease Agreement, dated December 30, 2020, by and between Ardelyx, Inc. and Prospect Fifth Ave, LLC. Exhibit 10.31 LEASE ? THIS INSTRUMENT IS A LEASE (including all exhibits, the ?Lease?), dated as of December 30, 2020 by and between Prospect Fifth Ave, LLC, a Massachusetts limited liability company, as (?Landlord?), and Ardelyx, Inc. a Delaware corporation, as (?Tenant?), which relates to space in the building known as 400 Fifth Avenue (the ?Building?) located in Waltham, Massachusetts. The part
February 16, 2021	SC 13G/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Ardelyx, Inc. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No.
February 16, 2021	SC 13G/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* ARDELYX, INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* ARDELYX, INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 039697107 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pur
February 12, 2021	SC 13G/A	SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 2) * Ardel SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No.
February 11, 2021	SC 13G/A	Ardelyx, Inc. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 3)* Ardelyx, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 039697107 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pursuant to whi
November 12, 2020	8-K	Other Events - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 12, 2020 ARDELYX, INC. (Exact name of registrant as specified in its charter) Delaware 001-36485 26-1303944 (State or other jurisdiction of incorporation) (Commission File Nu
November 5, 2020	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 5, 2020 ARDELYX, INC. (Exact name of registrant as specified in its charter) Delaware 001-36485 26-1303944 (State or other jurisdiction of incorporation) (Commission File Num
November 5, 2020	EX-99.1	Ardelyx Reports Third Quarter 2020 Financial Results and Business Highlights Tenapanor NDA Accepted for Review by FDA; PDUFA Goal Date set for April 29, 2021 Maintains strong balance sheet with $185.5 million in cash, cash equivalents and short-term EX-99.1 2 ardx-20201105xex99d1.htm EX-99.1 Exhibit 99.1 Ardelyx Reports Third Quarter 2020 Financial Results and Business Highlights Tenapanor NDA Accepted for Review by FDA; PDUFA Goal Date set for April 29, 2021 Maintains strong balance sheet with $185.5 million in cash, cash equivalents and short-term investments FREMONT, Calif., November 5, 2020 - Ardelyx, Inc. (Nasdaq: ARDX), a specialized bi
November 5, 2020	10-Q	Quarterly Report - 10-Q Table of Contents IncreaseDecreaseInContractWithCustomerLiability UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36485 ARDELYX, INC.
October 14, 2020	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 9, 2020 ARDELYX, INC. (Exact name of registrant as specified in its charter) Delaware 001-36485 26-1303944 (State or other jurisdiction of incorporation) (Commission File Numb
October 14, 2020	EX-10.1	First Amendment to Loan and Security Agreement, dated as of October 9, 2020, by and among Ardelyx, Inc., Solar Capital Ltd. and the lenders party Exhibit 10.1 FIRST AMENDMENT TO LOAN AND SECURITY AGREEMENT THIS FIRST AMENDMENT TO LOAN AND SECURITY AGREEMENT (this “Amendment”), dated as of October 9, 2020 (the “Amendment Effective Date”), is made by and among Ardelyx, Inc., a Delaware corporation (“Borrower”), Solar Capital Ltd., a Maryland corporation (“Solar”), in its capacity as collateral agent for Lenders (in such capacity, together wit
August 6, 2020	EX-10.4	Change in Control Severance Agreement, dated June 8, 2020, by and between Ardelyx, Inc. and Justin Renz Exhibit 10.4 ARDELYX, INC. CHANGE IN CONTROL SEVERANCE AGREEMENT This Change in Control Severance Agreement (the “Agreement”) is made and entered into by and between Justin Renz (the “Executive”) and Ardelyx, Inc. (the “Company”), effective as June 8, 2020 (the “Effective Date”). R E C I T A L S A. It is expected that the Company from time to time will consider the possibility of an acquisition by
August 6, 2020	10-Q	Quarterly Report - 10-Q Table of Contents IncreaseDecreaseInContractWithCustomerLiability UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER: 001-36485 ARDELYX, INC.
August 6, 2020	EX-10.5	Manufacturing Services Agreement, dated May 18, 2020, between Ardelyx, Inc. and Patheon Pharmaceuticals Inc. Exhibit 10.5 [***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. Manufacturing Services Agreement Effective Date: May 18, 2020 PARTIES PATHEON PHARMACEUTICALS INC. a corporation existing under the laws of the State of Delaw
August 6, 2020	EX-10.3	Offer Letter, dated June 2, 2020, by and between Ardelyx, Inc. and Justin Renz Exhibit 10.3 34175 Ardenwood Blvd Fremont, CA 94555 (510) 745-1700 – Tele (510) 745-0493 – Fax www.ardelyx.com June 2, 2020 Justin Renz 48 Walnut Street Milton, MA 02186 Dear Justin: On behalf of Ardelyx (the “Company”), I am pleased to offer you employment in the exempt position of Chief Financial Officer reporting to the Chief Executive Officer. This letter sets out the terms of Ardelyx’s offer
August 6, 2020	EX-10.2	Change in Control Severance Agreement dated June 2, 2020, by and between Ardelyx, Inc. and Susan Rodriguez Exhibit 10.2 ARDELYX, INC. CHANGE IN CONTROL SEVERANCE AGREEMENT This Change in Control Severance Agreement (the “Agreement”) is made and entered into by and between Susan Rodriguez (the “Executive”) and Ardelyx, Inc. (the “Company”), effective as May 18, 2020 (the “Effective Date”). R E C I T A L S A. It is expected that the Company from time to time will consider the possibility of an acquisitio
August 6, 2020	EX-99.1	Ardelyx Reports Second Quarter 2020 Financial Results and Recent Business Highlights Submitted a New Drug Application to the U.S. Food and Drug Administration for the review of tenapanor as a first-in-class therapy to control serum phosphorus in adul Exhibit 99.1 Ardelyx Reports Second Quarter 2020 Financial Results and Recent Business Highlights Submitted a New Drug Application to the U.S. Food and Drug Administration for the review of tenapanor as a first-in-class therapy to control serum phosphorus in adult patients with chronic kidney disease on dialysis Maintains strong balance sheet with $204.8 million in cash, cash equivalents and short
August 6, 2020	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2020 ARDELYX, INC. (Exact name of registrant as specified in its charter) Delaware 001-36485 26-1303944 (State or other jurisdiction of incorporation) (Commission File Numbe
August 6, 2020	EX-10.1	Offer Letter, dated April 27, 2020, by and between Ardelyx, Inc. and Susan Rodriguez Exhibit 10.1 34175 Ardenwood Blvd Fremont, CA 94555 (510) 745-1700 – Tele (510) 745-0493 – Fax www.ardelyx.com April 27, 2020 Susan Rodriguez Chicago, IL Dear Susan: On behalf of Ardelyx (the “Company”), I am pleased to offer you employment in the exempt position of Chief Commercial Officer reporting to the Chief Executive Officer, responsible for Commercial, Business Development and Alliance Mana
July 31, 2020	CORRESP	- CORRESP 1 filename1.htm Ardelyx, Inc. 34175 Ardenwood Boulevard Fremont, California 94555 July 30, 2020 VIA EDGAR AND E-MAIL United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549-6010 Attention: Jeffrey Gabor, Mary Beth Breslin Re: Ardelyx, Inc. Registration Statement on Form S-3 (Registration No. 333-239764) Ladies and Gentlemen
July 24, 2020	S-3/A	- S-3/A Table of Contents As filed with the Securities and Exchange Commission on July 23, 2020 Registration No.
July 23, 2020	CORRESP	- 140 Scott Drive Menlo Park, California 94025 Tel: +1.650.328.4600 Fax: +1.650.463.2600 www.lw.com FIRM / AFFILIATE OFFICES Beijing Moscow Boston Munich Brussels New York Century City Orange County Chicago Paris Dubai Riyadh July 23, 2020 Düsseldorf San Diego Frankfurt San Francisco Hamburg Seoul Hong Kong Shanghai Houston Silicon Valley London Singapore Los Angeles Tokyo Madrid Washington, D.C. Mi
July 9, 2020	EX-1.2	Open Market Sales AgreementSM, by and between Ardelyx, Inc. and Jefferies LLC, dated July 8, 2020. Exhibit 1.2 EXECUTION VERSION OPEN MARKET SALE AGREEMENTSM July 8, 2020 JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: Ardelyx, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the “Agent”), shares of the Company’s co
July 9, 2020	EX-4.4	Form of Indenture. Exhibit 4.4 ARDELYX, INC. INDENTURE Dated as of [⚫], 20[⚫] [⚫] Trustee TABLE OF CONTENTS Page ARTICLE I. DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.1. Definitions. 1 Section 1.2. Other Definitions. 4 Section 1.3. Incorporation by Reference of Trust Indenture Act. 4 Section 1.4. Rules of Construction. 5 ARTICLE II. THE SECURITIES 5 Section 2.1. Issuable in Series. 5 Section 2.2. Establi
July 9, 2020	S-3	Powers of Attorney (incorporated by reference to the signature page hereto). Table of Contents As filed with the Securities and Exchange Commission on July 8, 2020 Registration No.
June 18, 2020	SC 13D/A	ARDX / Ardelyx, Inc. / New Enterprise Associates 12, Limited Partnership - SCHEDULE 13D/A - AMENDMENT #6 Activist Investment SCHEDULE 13D/A - AMENDMENT #6 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
June 10, 2020	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 8, 2020 ARDELYX, INC. (Exact name of registrant as specified in its charter) Delaware 001‑36485 26‑1303944 (State or other jurisdiction of incorporation) (Commission File Number)
May 7, 2020	10-Q	Quarterly Report - 10-Q Table of Contents IncreaseDecreaseInContractWithCustomerLiability UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2020 OR ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER: 001‑36485 ARDELYX, INC.
May 7, 2020	EX-99.1	Ardelyx Reports First Quarter 2020 Financial Results and Recent Business Highlights Company maintains strong balance sheet with $223.2 million in cash, cash equivalents and short-term investments Exhibit 99.1 Ardelyx Reports First Quarter 2020 Financial Results and Recent Business Highlights Company maintains strong balance sheet with $223.2 million in cash, cash equivalents and short-term investments FREMONT, Calif., May 7, 2020 - Ardelyx, Inc. (Nasdaq: ARDX), a specialized biopharmaceutical company focused on developing innovative first-in-class medicines to improve treatment for people
May 7, 2020	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 7, 2020 ARDELYX, INC. (Exact name of registrant as specified in its charter) Delaware 001-36485 26-1303944 (State or other jurisdiction of incorporation) (Commission File Number)
April 27, 2020	DEFA14A	- DEFA14A DEFA14A 1 tmb-20200424xdefa14a.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only
April 27, 2020	DEF 14A	the information specifically incorporated by reference into our Annual Report on Form 10-K for the year ended December 31, 2019 from our Definitive Proxy Statement on Schedule 14A filed with the SEC on April 27, 2020; Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14
March 17, 2020	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 12, 2020 ARDELYX, INC. (Exact name of registrant as specified in its charter) Delaware 001‑36485 26‑1303944 (State or other jurisdiction of incorporation) (Commission File Numbe
March 10, 2020	S-8	ARDX / Ardelyx, Inc. S-8 - - S-8 S-8 As filed with the Securities and Exchange Commission on March 10, 2020 Registration No.
March 6, 2020	EX-10.30	Transition and Separation Agreement dated November 25, 2019, by and between the Company and Mark Kaufmann. Exhibit 10.30 TRANSITION AND SEPARATION AGREEMENT This Transition and Separation Agreement (the “Agreement”) by and between Mark Kaufmann (“Executive”) and Ardelyx, Inc. (the “Company”), is made effective as of the date Executive signs this Agreement (the “Effective Date”) with reference to the following facts: A. Executive currently serves as the Company’s Chief Financial Officer. B. Executive an
March 6, 2020	EX-99.1	Ardelyx Reports Fourth Quarter and Full Year 2019 Financial Results and Recent Highlights Exhibit 99.1 Ardelyx Reports Fourth Quarter and Full Year 2019 Financial Results and Recent Highlights FREMONT, Calif., March 06, 2020 - Ardelyx, Inc. (Nasdaq: ARDX), a specialized biopharmaceutical company focused on developing first-in-class medicines to improve treatment choices for people with cardiorenal diseases, today reported business highlights and financial results for the fourth quarter
March 6, 2020	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 6, 2020 ARDELYX, INC. (Exact name of registrant as specified in its charter) Delaware 001‑36485 26‑1303944 (State or other jurisdiction of incorporation) (Commission File Number
March 6, 2020	10-K	Form 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2019 OR ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER 001-36485
March 6, 2020	EX-4.4	Description of the Registrant’s Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934 Exhibit 4.4 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of December 31, 2019, Ardelyx, Inc. (“we,” “us,” or “our”) had one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended: our common stock, $0.0001 par value per share (“common stock”). Description of Capital Stock The follo
March 6, 2020	EX-21.1	Subsidiaries of the Registrant Exhibit 21.1 SUBSIDIARIES OF THE REGISTRANT Name Jurisdiction None
February 14, 2020	SC 13G	ARDX / Ardelyx, Inc. / RA Capital Management, LLC - SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* ARDELYX, INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 039697107 (CUSIP Number) December 31, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule purs
February 14, 2020	SC 13G/A	ARDX / Ardelyx, Inc. / Rock Springs Capital Management LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No.
February 13, 2020	SC 13G/A	ARDX / Ardelyx, Inc. / Flynn James E Passive Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No.
February 12, 2020	SC 13G/A	ARDX / Ardelyx, Inc. / Adage Capital Partners GP LLC - ARDELYX, INC. Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Ardelyx, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 039697107 (CUSIP Number) December 31, 2019 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pursuant to whi
February 12, 2020	SC 13G/A	ARDX / Ardelyx, Inc. / Future Fund Board of Guardians - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Ardelyx, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 039697107 (CUSIP Number) December 31, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pur
February 12, 2020	EX-99.1	JOINT FILING AGREEMENT Exhibit 99.1 JOINT FILING AGREEMENT This JOINT FILING AGREEMENT (this “Agreement”), is made and entered into as of July 21, 2016, by and between Future Fund Board of Guardians (“FFBG”) and Future Fund Investment Company No.4 Pty Ltd (“FF” and together with FFBG, the “FF Parties”). The FF Parties hereby acknowledge and agree that the Statement on Schedule 13G to which this Agreement is attached as
January 13, 2020	8-K	Results of Operations and Financial Condition OldOld UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 13, 2020 ARDELYX, INC. (Exact name of registrant as specified in its charter) Delaware 001-36485 26-1303944 (State or other jurisdiction of incorporation) (Commission F
December 5, 2019	424B5	20,000,000 Shares Common Stock 424B5 1 d843167d424b5.htm PROSPECTUS FILED PURSUANT TO RULE 424(B)(5) Table of Contents Filed pursuant to Rule 424(b)(5) Registration Statement No. 333-217441 PROSPECTUS SUPPLEMENT (To Prospectus dated May 4, 2017) 20,000,000 Shares Common Stock We are offering 20,000,000 shares of our common stock. Our common stock is listed on The Nasdaq Global Market under the symbol “ARDX.” On December 4, 2019
December 5, 2019	424B5	SUBJECT TO COMPLETION, DATED DECEMBER 4, 2019 424B5 1 d843167d424b5.htm PROSPECTUS SUPPLEMENT FILED PURSUANT TO RULE 424(B)(5) Table of Contents Filed pursuant to Rule 424(b)(5) Registration Statement No. 333-217441 The information in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement is not an offer to sell nor does it seek an offer to buy these securities in any jurisdiction whe
December 5, 2019	8-K	Financial Statements and Exhibits, Other Events 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 4, 2019 ARDELYX, INC. (Exact name of registrant as specified in its charter) Delaware 001-36485 26-1303944 (State or other jurisdiction of incorporation) (Commission File
December 5, 2019	EX-1.1	Underwriting Agreement, dated as of December 4, 2019, among Ardelyx, Inc., Citigroup Global Markets Inc., Cowen and Company LLC, SVB Leerink LLC, and Piper Jaffray & Co., as representatives of the underwriters named therein. EX-1.1 Exhibit 1.1 Ardelyx, Inc. UNDERWRITING AGREEMENT December 4, 2019 CITIGROUP GLOBAL MARKETS INC. COWEN AND COMPANY, LLC SVB LEERINK LLC PIPER JAFFRAY & CO. As Representatives of the several Underwriters listed in Schedule A hereto c/o Citigroup Global Markets Inc. 388 Greenwich Street New York, New York 10013 c/o Cowen and Company, LLC 599 Lexington Avenue New York, New York 10022 c/o SVB Le
December 3, 2019	EX-99.1	Forward-Looking Statements To the extent that statements contained in this presentation are not descriptions of historical facts regarding Ardelyx, they are forward-looking statements reflecting the current beliefs and expectations of management made EX-99.1 Exhibit 99.1 Forward-Looking Statements To the extent that statements contained in this presentation are not descriptions of historical facts regarding Ardelyx, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor of the Private Securities Reform Act of 1995, including statements regarding the potential for Ardel
December 3, 2019	8-K	Regulation FD Disclosure, Financial Statements and Exhibits 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 3, 2019 ARDELYX, INC. (Exact name of registrant as specified in its charter) Delaware 001-36485 26-1303944 (State or other jurisdiction of incorporation) (Commission File
December 3, 2019	8-K	Other Events 8-K 1 d843175d8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 3, 2019 ARDELYX, INC. (Exact name of registrant as specified in its charter) Delaware 001-36485 26-1303944 (State or other jurisdiction of incorporat
December 2, 2019	8-K	Unregistered Sales of Equity Securities, Other Events Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 25, 2019 ARDELYX, INC. (Exact name of registrant as specified in its charter) Delaware 001-36485 26-1303944 (State or other jurisdiction of incorporation) (Commissio
November 26, 2019	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 25, 2019 ARDELYX, INC. (Exact name of registrant as specified in its charter) Delaware 001-36485 26-1303944 (State or other jurisdiction of incorporation) (Commission Fil
November 6, 2019	10-Q	November 6, 2019 Table of Contents IncreaseDecreaseInContractWithCustomerLiability UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2019 OR ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER: 001‑36485 ARDELYX, INC.
November 6, 2019	EX-99.1	Ardelyx Reports Third Quarter 2019 Financial Results and Recent Highlights PHREEDOM clinical trial to read out this quarter Exhibit 99.1 Ardelyx Reports Third Quarter 2019 Financial Results and Recent Highlights PHREEDOM clinical trial to read out this quarter FREMONT, Calif., November 6, 2019 - Ardelyx, Inc. (Nasdaq: ARDX), a specialized biopharmaceutical company focused on developing first-in-class medicines to improve treatment choices for people with cardiorenal diseases, today reported business highlights and fina
November 6, 2019	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 6, 2019 ARDELYX, INC. (Exact name of registrant as specified in its charter) Delaware 001-36485 26-1303944 (State or other jurisdiction of incorporation) (Commission File Num
September 27, 2019	SC 13G	ARDX / Ardelyx, Inc. / Rock Springs Capital Management LP Passive Investment SC 13G 1 rocksprings-ardx091719.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Ardelyx, Inc. (Name of Issuer) Common Stock, par value, $0.0001 per share (Title of Class of Securities) 039697107 (CUSIP Number) September 17, 2019 (Date of Event Which Requires Filing of this Statement) Check the approp
September 13, 2019	8-K	Other Events 8-K 1 f8-k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 12, 2019 ARDELYX, INC. (Exact name of registrant as specified in its charter) Delaware 001-36485 26-1303944 (State or other jurisdiction of incorporation)

ARDX / Ardelyx, Inc. - Depositi SEC, Relazione annuale, dichiarazione di delega

Statistiche di base

SEC Filings

SEC Filings (Chronological Order)

Other Listings

MX:ARDX
DE:41X	5,52 €